AG
CTKB icon

Algert Global’s Cytek Biosciences CTKB Stock Holding History

Algert Global’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66K Sell
14,895
-27,665
-65% -$118K ﹤0.01% 1231
2026
Q1 		$186K Buy
+42,560
New +$201K ﹤0.01% 1090
2025
Q3 		– Sell
-372,238
Closed -$1.27M – 1169
2025
Q2 		$1.27M Sell
372,238
-39,187
-10% -$131K 0.03% 756
2025
Q1 		$1.65M Buy
411,425
+60,510
+17% +$314K 0.04% 655
2024
Q4 		$2.28M Buy
350,915
+21,540
+7% +$128K 0.05% 562
2024
Q3 		$1.82M Buy
329,375
+34,100
+12% +$193K 0.05% 579
2024
Q2 		$1.65M Buy
295,275
+168,665
+133% +$1.01M 0.05% 525
2024
Q1 		$850K Buy
126,610
+14,350
+13% +$113K 0.03% 654
2023
Q4 		$1.02M Buy
+112,260
New +$707K 0.04% 613
2023
Q2 		– Sell
-25,679
Closed -$236K – 1116
2023
Q1 		$236K Sell
25,679
-47,634
-65% -$512K 0.01% 994
2022
Q4 		$749K Buy
73,313
+27,258
+59% +$366K 0.04% 683
2022
Q3 		$678K Buy
46,055
+24,785
+117% +$322K 0.04% 706
2022
Q2 		$228K Buy
+21,270
New +$212K 0.02% 989

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Algert Global's CTKB Position: Q2 2026 in Review

Algert Global reduced its Cytek Biosciences (CTKB) stake by 65% in Q2 2026, selling an estimated $118K and leaving 14,895 shares worth $66K. The position accounts for ﹤0.01% of the portfolio, ranked #1231.

Algert Global first reported a position in CTKB in Q2 2022 and has held it in 13 quarters since. The position peaked at $2.28M in Q4 2024. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Algert Global held 14,895 shares of Cytek Biosciences worth $66K as of Q2 2026.
  • Algert Global sold 27,665 Cytek Biosciences shares in Q2 2026, an estimated $118K.
  • Cytek Biosciences made up ﹤0.01% of Algert Global's portfolio in Q2 2026, its #1231 holding.
  • Algert Global first reported a position in Cytek Biosciences in Q2 2022 and has held it in 13 quarters since.
  • Algert Global's Cytek Biosciences position peaked at $2.28M in Q4 2024.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.